CureDuchenne continued funding a robust Duchenne drug development pipeline with a new investment in Entrada Therapeutics as part of their latest financing from a group of investors.
Entrada Therapeutics’ promising technology can be applied to a wide array of diseases, so we are thrilled that Entrada’s team has set their sights on Duchenne as their lead indication. Entrada will use funding from CureDuchenne to advance its lead Duchenne exon-skipping oligonucleotide program to the clinic.
CureDuchenne Ventures believes in the importance of having a robust pipeline with multiple shots on goal, and in the promise of safe and effective exon-skipping therapies to restore dystrophin in cardiac and skeletal muscle. As a proud funder and collaborator in their Duchenne program, we will keep the community updated on their progress!